Semaglutide Effect on Hepatic Fat in Obese MASLD Patients

Phase 3, single-arm trial of semaglutide in obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Institute for Clinical and Experimental Medicine. Primary endpoints: Change in hepatic fat content and hepatic fat volume after 14 and 16 weeks of semaglutide and Acute response of hepatic fat content to high-fat load with and without glucose co-administration. Planned start Jun 2023; status: authorised.